Hovione reported today recent capacity expansion and future plans in its sites in Portugal, Ireland and New Jersey.
Interview: Colin Minchom, VP, Particle Design Business Unit
“An issue for customers with a poorly soluble molecule is that any one solubility enhancement technology is likely to have, I believe, a 20% to 40% probability of solving the problem. This means that in order to assure acceptable bioavailability, at least three technologies need to be investigated. The customer would need to contract with three single platform technology companies or be able to engage a single company, such as Hovione, that can apply multiple platforms, to increase the probability of solving the problem, and deliver the desired outcome.”